EspaƱa
India
Italia
ėķ민źµ
ę„ę¬
My Account
Benzinga Edge
Benzinga Research
Benzinga Pro
Login
Get Benzinga Pro
Data & APIs
Events
Premarket
Advertise
Contribute
EspaƱa
India
Italia
ėķ민źµ
ę„ę¬
Login
Register
Our Services
News
Earnings
Guidance
Dividends
M&A
Buybacks
Legal
Interviews
Management
Offerings
IPOs
Insider Trades
Biotech/FDA
Politics
Healthcare
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Binary Options
Bonds
Futures
CME Group
Global Economics
Mining
Previews
Small-Cap
Real Estate
Penny Stocks
Digital Securities
Volatility
Options
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Whisper Index
Stock of the Day
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Prop Trading
Credit Cards
Stock Brokers
Crypto
News
Earnings
Guidance
Dividends
M&A
Buybacks
Legal
Interviews
Management
Offerings
IPOs
Insider Trades
Biotech/FDA
Politics
Healthcare
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Binary Options
Bonds
Futures
CME Group
Global Economics
Mining
Previews
Small-Cap
Real Estate
Penny Stocks
Digital Securities
Volatility
Options
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Whisper Index
Stock of the Day
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Prop Trading
Credit Cards
Stock Brokers
Crypto
Research
My Stocks
Tools
Free Benzinga Pro Trial
Calendars
Analyst Ratings Calendar
Conference Call Calendar
Dividend Calendar
Earnings Calendar
Economic Calendar
FDA Calendar
Guidance Calendar
IPO Calendar
M&A Calendar
SPAC Calendar
Stock Split Calendar
Trade Ideas
Free Stock Reports
Insider Trades
Trade Idea Feed
Analyst Ratings
Unusual Options Activity
Heatmaps
Free Newsletter
Government Trades
Perfect Stock Portfolio
Easy Income Portfolio
Short Interest
Most Shorted
Largest Increase
Largest Decrease
Calculators
Margin Calculator
Forex Profit Calculator
100x Options Profit Calculator
Screeners
Stock Screener
Top Momentum Stocks
Top Quality Stocks
Top Value Stocks
Top Growth Stocks
Recent
Markets
Joshua Schimmer
Piper Jaffray Thinks It Might Be A Good Time For BioMarin To Sell Itself
Could Regenxbio Shares Have 320% Upside?
The Plot Thickens At Amgen; Piper Still Overweight
Could Regenxbio Shares Have 320% Upside?
The Plot Thickens At Amgen; Piper Still Overweight
Chimerix: Piper's 'Post-Blow-Up' Play
Piper Jaffray: Valeant's Business Could Be Broken Up In 2016
Chimerix: Piper's 'Post-Blow-Up' Play
|
Piper Jaffray: Valeant's Business Could Be Broken Up In 2016
|
Piper Jaffray: Akorn's Stock Will Be Delisted In 2016
|
Piper Jaffray Makes 15 'Provocative' Predictions For Biopharma Sector In 2016
|
Read More...
Joshua Schimmer Recent News
Bluebuird Bio Crashes Nearly 30%: What's Next?
|
5 Biotechs That Can Win From Ophthalmology Innovation
|
Calls Of Note: The Research Moving Stocks Today
|
Piper Jaffray On Biogen Downgrade: '6 MG Data Does Not Inspire Confidenceā¦Even More Speculative Than Before'
|
Piper Jaffray Dishes On MannKind's Afrezza Data
|
Biogen Or Bluebird: Which Will Lead In SCD?
|
Piper Jaffray Names Chimerix Inc Top Ebola Play
|
Piper Jaffray Not Convinced MannKind's Afreeza Will Be Commercial Success
|
Shares of MannKind Plummet Prior to Drug Advisory Meeting
|
Piper Sees "Meaningful Utility" from GW Phamaceuticals CBD, Reiterates Overweight Rating
|
UPDATE: Piper Jaffray Initiates On Amgen On Series Of Bold Steps
|
UPDATE: Piper Jaffray Initiates on Alexion on High Revenue and EPS Growth Rates
|
UPDATE: Piper Jaffray Initiates On BioMarin Pharmaceuticals On BMN-111 Outlook
|
UPDATE: Piper Jaffray Maintains Overweight On Vanda Pharmaceuticals On Hetlioz Outlook
|
Lazard Capital Markets Reiterates Buy on Vanda Pharmaceuticals on Good Entry Point
|
Leerink Swann Reiterates Incyte (INCY) Outperform Rating
|
Leerink Swann Reiterates Gilead Science (GILD) Outperform Rating
|